

**Amendments to the claims.**

Please amend the claims as follows:

1-3. (canceled)

4. (previously presented) The formulation according to claim 24, wherein said liposome comprises a polyethyleneglycol derivative of diacylphosphatidylethanolamine.

5. (previously presented) The formulation according to claim 4, wherein the polyethyleneglycol has a molecular weight between about 500 and 5000 daltons.

6. (currently amended) ~~The~~ A formulation according to claim 24, wherein the molar ratio is 10:3 which comprises an anti HLA-DR antibody molecule coupled to a liposome, said antibody molecule being selected from the group consisting of a whole antibody and an antigen binding fragment thereof, said formulation capable of binding to an HLA-DR protein present at both the surface of an infectious agent and at the membrane surface of a cell, wherein said liposome comprises a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio of about 10:3 and the acyl chains are either saturated or unsaturated and 14-18 carbon atoms in length.

7. (previously presented) The formulation according to claim 4, wherein said liposome comprises a mixture of diacylphosphatidylcholine: diacylphosphatidylglycerol: diacylphosphatidylethanol-amine-polyethyleneglycol in a molar ratio of 10:3:0.1-3.

8. (previously presented) The formulation according to claim 24, wherein said liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol in a molar ratio of 10:3 or distearoylphosphatidylcholine:distearoylphosphatidylglycerol in a molar ratio of 10:3.

9. (currently amended) The A formulation according to claim 24, which comprises an anti-HLA-DR antibody molecule coupled to a liposome, said antibody molecule being selected from the group consisting of a whole antibody and an antigen binding fragment thereof, said formulation capable of binding to an HLA-DR protein present at both the surface of an infectious agent and at the membrane surface of a cell, wherein said liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol: dipalmitoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.33 or dipalmitoylphosphatidylcholine: dipalmitoylphosphatidylglycerol: distearoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.83.

10. (previously presented) The formulation according to claim 24, further comprising an additional antibody molecule to one or more proteins selected from a histocompatibility complex protein, a membrane ATPase, thy-1, an interleukin receptor, annexin II, CD3 (T3), CD4 (T4), CD5 (Ti), CD6 (T12), CD8 (T8), CD11a (LFA-1), CD11b (Mac-1), CD11c (gp150,95), CD1 (Lewis X), CD18, CD19, CD25 (Tac), CD30 (Ki-1), CD43 (leukosialin, sialophorin), CD44 (Pgp-1), CD48 (Blast-1), CD54 (ICAM-1), CD55 (DAF), CD59 (protectin, Mac inhibitor), CD63, CD71 (transferrin receptor), CDw108(GR2), cyclophilin A, cytoskeletal proteins and  $\beta$  2-microglobulin.

11. (canceled)

12. (previously presented) The formulation according to claim 24, which further comprises a drug effective against a disease or against the symptoms of a disease caused by said an infectious agent.

13. (previously presented) The formulation according to claim 24, wherein said HLA-DR protein is present at the membrane surface of a lymphoid cell or a cell of the reticuloendothelial system.

14. (previously presented) The formulation according to claim 12, wherein said HLA-DR protein is present at the membrane surface of a lymphoid cell or a cell of the reticuloendothelial system.

15. (previously presented) The formulation according to claim 13, wherein said HLA-DR protein is acquired by HIV.

16. (previously presented) The formulation according to claim 14, wherein said HLA-DR protein is acquired by HIV.

17. (previously presented) The formulation according to claim 13, further comprising an additional antibody molecule to one or more of CD4, MHC-I and CD54 proteins.

18. (previously presented) The formulation according to claim 14, further comprising an additional antibody molecule to one or more of CD4, MHC-I and CD54 proteins.

19. (previously presented) The formulation according to claim 12, wherein said drug is selected from AZT, ddI, ddC, 3TC, indinavir, saquinavir, zidovudine, zalcitabine, didanosine, zalcitabine, foscarnet, ribavirin, amphotericin B and nystatin A.

20. (previously presented) The formulation according to claim 24, wherein said antibody molecule is an anti-Fab' antibody fragment directed against a HLA-DR protein.

21 - 23. (canceled)

24. (currently amended) A formulation which comprises an anti HLA-DR antibody molecule coupled to a liposome, said antibody molecule being selected from the group consisting of a whole antibody and an antigen binding fragment thereof, said formulation capable of binding to an HLA-DR protein present at both the surface of an infectious agent and at the membrane surface of a cell, wherein said liposome comprises a mixture of diacylphosphatidylcholine and

diacylphosphatidylglycerol in a molar ratio of ~~about~~ between 10:1 to 1:1 and the acyl chains are either saturated or unsaturated and 14-18 carbon atoms in length.

25. (previously presented) The formulation of claim 24, wherein said infectious agent is HIV.

26. (currently amended) A formulation which comprises an anti HLA-DR antibody molecule coupled to a liposome, said antibody molecule being selected from the group consisting of a whole antibody and an antigen binding fragment thereof, said formulation capable of binding to an HLA-DR protein present at both the surface of an infectious agent and at the membrane surface of a cell and of delivering a drug to said cell and infectious agent, wherein said liposome comprises a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio of ~~about~~ between 10:1 to 1:1 and the acyl chains are either saturated or unsaturated and 14-18 carbon atoms in length.

27. (previously presented) The formulation of claim 26, wherein said infectious agent is HIV.